Literature DB >> 5109448

Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy.

C B Pratt, W W Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5109448     DOI： 10.1002/1097-0142(197108)28:2<361::aid-cncr2820280215>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  10 in total

1.  Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.

Authors:  Y Liu; C A Fernandez; C Smith; W Yang; C Cheng; J C Panetta; N Kornegay; C Liu; L B Ramsey; S E Karol; L J Janke; E C Larsen; N Winick; W L Carroll; M L Loh; E A Raetz; S P Hunger; M Devidas; J J Yang; C G Mullighan; J Zhang; W E Evans; S Jeha; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

2.  Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of acute lymphoblastic leukaemia.

Authors:  P G Johnston; R M Hardisty; H E Kay; P G Smith
Journal:  Br Med J       Date:  1974-07-13

3.  Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.

Authors:  Natasha Kamal; Christopher Koh; Niharika Samala; Robert J Fontana; Andrew Stolz; Francisco Durazo; Paul H Hayashi; Elizabeth Phillips; Tongrong Wang; Jay H Hoofnagle
Journal:  Hepatol Int       Date:  2019-08-07       Impact factor: 6.047

Review 4.  Drug-induced liver disease.

Authors:  H J Zimmerman
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 5.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

6.  Severe hepatotoxicity from Escherichia coli L-asparaginase.

Authors:  R Jenkins; E Perlin
Journal:  J Natl Med Assoc       Date:  1987-07       Impact factor: 1.798

7.  A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.

Authors:  Vilmarie Rodriguez; John Kairalla; Wanda L Salzer; Elizabeth A Raetz; Mignon Lc Loh; Andrew J Carroll; Nyla A Heerema; Brent L Wood; Michael J Borowitz; Michael J Burke; Barbara L Asselin; Meenakshi Devidas; Naomi J Winick; William L Carroll; Stephen P Hunger; ZoAnn E Dreyer
Journal:  J Pediatr Hematol Oncol       Date:  2016-08       Impact factor: 1.289

8.  Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity?

Authors:  Zeynep Canan Özdemir; Ayşe Bozkurt Turhan; Makbule Eren; Özcan Bor
Journal:  Blood Res       Date:  2017-03-27

9.  Mechanistic studies of PEG-asparaginase-induced liver injury and hepatic steatosis in mice.

Authors:  Gundala Venkata Naveen Kumar; Keito Hoshitsuki; Sanjay Rathod; Manda J Ramsey; Lauren Kokai; Erin E Kershaw; Wen Xie; Christian A Fernandez
Journal:  Acta Pharm Sin B       Date:  2021-12-04       Impact factor: 11.413

10.  Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.

Authors:  Rachael Schulte; Ashley Hinson; Van Huynh; Erin H Breese; Joanna Pierro; Seth Rotz; Benjamin A Mixon; Jennifer L McNeer; Michael J Burke; Etan Orgel
Journal:  Cancer Med       Date:  2021-09-16       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.